Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . CONSUN 康 臣 康 臣 葯業 集團 有限公司 CONSUN PHARMACEUTICAL GROUP LIMITED ( Incorporated in the Cayman Islands with limited liability ) ( Stock code : 1681 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021 FINANCIAL HIGHLIGHTS Revenue for the six months ended 30 June 2021 amounted to RMB886,526,000 , representing an increase of approximately 15.8 % as compared with the six months ended 30 June 2020 . Profit attributable to equity shareholders of the Company for the six months ended 30 June 2021 amounted to RMB250,644,000 , representing an increase of approximately 20.0 % as compared with the six months ended 30 June 2020 . Basic and diluted earnings per share for the six months ended 30 June 2021 amounted to approximately RMB0.3132 and RMB0.3117 respectively , representing an increase of approximately 23.9 % and 23.3 % respectively as compared with the six months ended 30 June 2020 . The Board has declared an interim dividend of HKD0.1 per share for the six months ended 30 June 2021 . INTERIM RESULTS The board ( the “ Board ” ) of directors ( the “ Directors ” ) of Consun Pharmaceutical Group Limited ( the " Company " ) is pleased to announce the unaudited consolidated financial results of the Company and its subsidiaries ( collectively the “ Group ” , “ Consun ” or “ Consun Pharmaceutical " ) for the six months ended 30 June 2021 ( the " Interim Results " ) . The audit committee of the Company ( the " Audit Committee ” ) and the Group's external auditor have reviewed the Interim Results . 1